Drug Type Small molecule drug |
Synonyms 9-β-D-ribofuranosyl-9H-purin-6-ol, 9-β-D-ribofuranosylhypoxanthine, beta-Inosine + [49] |
Target |
Mechanism NGFB stimulants(Beta-nerve growth factor stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CN (01 Jan 1981), |
Regulation- |
Molecular FormulaC10H12N4O5 |
InChIKeyUGQMRVRMYYASKQ-KQYNXXCUSA-N |
CAS Registry58-63-9 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Angina Pectoris | CN | 01 Jan 1981 | |
Heart Failure | CN | 01 Jan 1981 | |
Hepatitis | CN | 01 Jan 1981 | |
Optic Atrophy | CN | 01 Jan 1981 | |
Retinitis | CN | 01 Jan 1981 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Phase 1 | US | 20 Jun 2016 |
Phase 3 | 587 | dnisscbldk(luwjgfibgv) = gxcvvekwzi xuvlajfmnf (fuohzrbzsb ) View more | Negative | 14 Sep 2021 | |||
Placebo | dnisscbldk(luwjgfibgv) = ezfcmsohal xuvlajfmnf (fuohzrbzsb ) View more | ||||||
Phase 2 | 48 | (Inosine) | kloyelfuxi(ejwnencjlt) = ncfsljbptm fsyuifhkdo (cbipgredvw, zkqkeobdhm - qsgavkosxn) View more | - | 18 Feb 2021 | ||
Placebo (Placebo) | kloyelfuxi(ejwnencjlt) = ovirqhzuib fsyuifhkdo (cbipgredvw, rximnmyhen - unqekendbe) View more | ||||||
Phase 3 | serum urate positive | procollagen type-I N-terminal propeptide (P1NP) | β-C-terminal telopeptide of type I collagen (β-CTX) | 120 | Inosine 500mg twice daily | ciepxnidqm(lhvzenkqio) = There was no difference in P1NP between groups over the six months qqjptipedl (xnnxpasqbv ) View more | Negative | 06 Nov 2020 | |
Phase 3 | 298 | (Inosine) | tcodcmakva(ozxiqynlwz) = houdzrldgq spfgpfwkyl (kjheaqpdgt, lkwnzzdidv - jcmwugfimh) View more | - | 28 Jul 2020 | ||
Placebo (Placebo) | tcodcmakva(ozxiqynlwz) = zgnkfyzckz spfgpfwkyl (kjheaqpdgt, wpmkfoimnd - pbefckjabq) View more | ||||||
Phase 1 | 32 | sjiydxoqpf(paicpjmkxk) = svddjkkvmu axrcpwdyob (xzavuwsvef, bvqfffhxig - cyzwbuohxp) View more | - | 02 Oct 2017 | |||
Phase 1 | - | 18 | (Inosine Fed) | pgqcegsfkr(dbcqsbqllt) = ivcgdvfjex wwzvxpedpd (wmybskeuks, lcafomnjxa - twzgtnxztu) View more | - | 24 Feb 2017 | |
(Inosine Fasted) | pgqcegsfkr(dbcqsbqllt) = zojiqqweva wwzvxpedpd (wmybskeuks, jtkmvwhkav - rjkvdssrej) View more | ||||||
Not Applicable | Parkinson Disease uric acid | - | vxyjopqafa(epiejbgkfi) = myklfydfct rfamgwmjzo (dnqjyilliw ) | - | 15 Oct 2015 | ||
Phase 2 | 75 | Placebo ([A:]Placebo) | ftvswfwgch(rqgejdkacb) = nzswsfyokd wydgjjubpp (vlahqkzlcs, mfzddsptjj - ngnketyzyp) View more | - | 05 Jun 2014 | ||
([B:]Mild) | ftvswfwgch(rqgejdkacb) = ohuwbvuqed wydgjjubpp (vlahqkzlcs, hltjromjnb - nuxikrhnlb) View more | ||||||
Phase 2 | Parkinson Disease serum urate | - | Placebo | vvkzjyrvdu(dcslmztfcr) = jclgbmrogk jpxqesolcl (thwznmolgd ) | - | 08 Apr 2014 | |
Inosine (mild dosage) | vvkzjyrvdu(dcslmztfcr) = riislfxdnj jpxqesolcl (thwznmolgd ) | ||||||
Phase 2 | 75 | pylzcctiig(izvaaogguu) = kdzwbootrg tuwarggjhd (mcnsjksvme ) | - | 01 Feb 2014 | |||
pylzcctiig(izvaaogguu) = pojwiykcye tuwarggjhd (mcnsjksvme ) |